397; P < 0 001) and diagnostic category (AC versus FA group; b

397; P < 0.001) and diagnostic category (AC versus FA group; beta = 0.347; P < 0.001) were significant determinants of iris volume change.\n\nCONCLUSIONS. With physiologic mydriasis, the iris volume decreased in eyes with chronic

angle closure but remained unchanged in fellow eyes of APAC. Such variations in iris volume responses may influence the subtype of angle closure that develops. (Invest Torin 2 nmr Ophthalmol Vis Sci. 2013; 54: 708-713) DOI:10.1167/iovs.12-10844″
“Background: Inflammatory breast cancer (IBC) represents the most aggressive presentation of breast cancer. Women diagnosed with IBC typically have a poorer prognosis compared with those diagnosed with non-IBC tumors. Recommendations and guidelines published to date on the diagnosis, management, and follow-up of women with breast cancer have focused primarily on non-IBC tumors. Establishing a minimum standard for clinical diagnosis and treatment of IBC is needed.\n\nMethods: Recognizing IBC to be a distinct entity, a group of international experts met in December 2008 at the First International Conference on Inflammatory Breast Cancer to develop guidelines for the management of IBC.\n\nResults: The panel of leading IBC experts formed a consensus on the minimum requirements to accurately diagnose IBC, supported by selleckchem pathological

confirmation. In addition, the panel emphasized a multimodality approach of systemic chemotherapy, surgery, and radiation therapy.\n\nConclusions: The goal of these guidelines, based on an expert consensus after careful review of published data, is to help the clinical diagnosis of this rare disease and to standardize management of

IBC among treating physicians in both the academic and community settings.”
“Inhibitor 2 of protein phosphatase 2A (I2PP2A), a biological inhibitor of the cellular serine/threonine protein phosphatase PP2A, is associated with numerous cellular processes that often lead to the formation and progression of cancer. In this study we hypothesized that targeting the inhibition of I2PP2A’s multiple functions in prostate cancer cells might prevent cancer selleck chemical progression. We have investigated the effect of the small chain C6-ceramide, known to be a bioactive tumor suppressor lipid, on I2PP2A function, thereby affecting c-Myc signaling and histone acetylation in cells. Our data indicated that C6-ceramide treatment of prostate cancer cells induces cell death in PC-3, DU145, and LNCaP cells, but not normal prostate epithelial cells. C6-ceramide was able to disrupt the association between PP2A and I2PP2A. C6-ceramide inhibits I2PP2A’s upregulation of c-Myc and downregulation of histone acetylation in prostate cancer cells. Our data indicated that targeting cancer related signaling pathways through I2PP2A using ceramide as an anti-I2PP2A agent could have beneficial effects as a therapeutic approach to prevent prostate cancer.

Comments are closed.